Oncology Institute (TOIIW) Enterprise Value (2019 - 2026)

Oncology Institute has reported Enterprise Value for 8 years, with the latest figure at -$30.3 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value rose 23.8% year-over-year to -$30.3 million; the trailing twelve-month figure through Mar 2026 stood at -$30.3 million (up 23.8% YoY), and the FY2025 full-year result was -$33.6 million, up 32.42% from the prior year.
• Enterprise Value for Q1 2026 stood at -$30.3 million, up from -$33.6 million in the prior quarter.
• The five-year high for Enterprise Value was -$27.7 million in Q3 2025, with the low at -$95.5 million in Q1 2022.
• Historically, Enterprise Value has averaged -$56.5 million across 5 years, with a median of -$49.7 million in 2024.
• Annual changes were most pronounced in 2022 — Enterprise Value sank 685.46% — and 2024, when it jumped 45.77%.
• Oncology Institute's Enterprise Value stood at -$73.8 million in 2022, then decreased by 12.26% to -$82.9 million in 2023, then soared by 40.05% to -$49.7 million in 2024, then jumped by 32.42% to -$33.6 million in 2025, then increased by 9.79% to -$30.3 million in 2026.
• The last three Enterprise Value figures came in at -$30.3 million (Q1 2026), -$33.6 million (Q4 2025), and -$27.7 million (Q3 2025), per Business Quant data.